Our purpose is to progress iconic medicines for the benefit of patient health globally. We aspire to be an agile and imaginative specialty pharma business and a preferred partner for innovator pharma companies.
More about us10+
Offices
20+
Brands
140+
Markets
200+
Employees
Our key products include Inderal®, Tenormin®, Tenoretic®, Zestril®and Zestoretic®
Our key products include Bonviva®, Rocaltrol® and Synacthen®
Our key products include Anaprox®, Naprosyn®, Toradol® and Valium®
Our key products include Bondronat®, Dipentum® and Kytril®
We work with innovator pharma companies on the late stage activities of development, co-development, licensing and established brand acquisition. We aim to be open, approachable and collaborative. We pride ourselves on our entrepreneurial heritage and we retain a dynamic, motivated and “can do” attitude. We have an enviable track record and repeat transactions bear testament to our status as a preferred partner.
For Trade and Medical Media ONLY PHARMANOVIA EXCLUSIVELY LICENCES RIGHTS FOR A NOVEL WAY OF TREATING...
More informationDKSH will support life cycle management company Pharmanovia in its mission to bring important medication to...
More informationLondon (UK), 20 June 2022 Ian King interviews Pharmavovia’s CEO, Dr James Burt on SkyNews
More informationWe are an experienced group of people with a can-do attitude. We believe in openness, honesty and courtesy, and value collaboration above all else. If you are a motivated and dynamic individual, we can empower you and you will thrive with us.
We are proud to be a member of EMIG, the Ethical Medicines Industry Group.
Learn more at emig.org.uk
Benelux site
